COV-ENT-1 / Enterin - LARVOL DELTA

Enterin to conduct a randomized phase 1/2a study in hospitalized patients with Covid-19 (PRNewswire) - "Enterin, Inc....announced today that it has received feedback from the FDA laying out the path for a Phase 1/2a study in hospitalized patients with COVID-19 infection. The study will involve 10 U.S. sites and will enroll 80 hospitalized patients. Patients will have been diagnosed with SARS-CoV-2, have an SpO2 ≤94% or evidence of pneumonia by chest XR or CT scan. The first stage will involve 24 patients....The second stage will involve another 56 patients....The compound is administered by inhalation via standard nebulizer....Assuming Enterin is allowed to proceed with the study, it is anticipated that the study will begin within the next three months."

FDA event • New P1/2 trial • Infectious Disease • Novel Coronavirus Disease